Coya Therapeutics (COYA) Other Accumulated Expenses (2025)

Coya Therapeutics (COYA) reported Other Accumulated Expenses of $43139.0 for Q4 2025.

Coya Therapeutics (COYA) Other Accumulated Expenses (2025) Analysis & Trends

Coya Therapeutics (COYA) has 1 years of Other Accumulated Expenses data on file, last reported at $43139.0 in Q4 2025.

For the quarter ending Q4 2025, Other Accumulated Expenses changed N/A year-over-year to $43139.0; the trailing twelve-month figure through Dec 2025 stood at $43139.0 (changed N/A YoY), and the FY2025 full-year result was $43139.0, changed N/A from the prior year.
Other Accumulated Expenses steadied at $43139.0 in Q4 2025.
In the past five years, Other Accumulated Expenses ranged from a high of $43139.0 in Q4 2025 to a low of $43139.0 in Q4 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,681.27 Bn	66,680.98 Bn	-
2	Nanobiotix	1,911.83 Bn	1,911.77 Bn	-
3	Akari Therapeutics	959.56 Bn	959.56 Bn	-
4	BeOne Medicines	472.75 Bn	467.96 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.14 Bn	114.89 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.09 Bn	61.34 Bn	3.31 Bn
7	Belite Bio	62.34 Bn	62.34 Bn	-
8	Argenx Se	55.94 Bn	50.76 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.52 Bn	34.51 Bn	959.66 Mn
10	Coya Therapeutics	97.71 Mn	46.99 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2025	43,139.00